Latest news with #AuronTherapeutics
Yahoo
29-04-2025
- Business
- Yahoo
Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting
NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced preclinical data in prostate cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. Using a series of experiments, Auron demonstrated activity with AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine prostate cancer (NEPC) and castrate resistant prostate cancer (CRPC). In NEPC cell lines and PDXO models treated for up to 21 days, AUTX-703 mediated potent KAT2A/KAT2B degradation, inhibited cell growth and induced cell state differentiation. AUTX-703 alone or in combination with enzalutamide was also found to induce cell differentiation in androgen receptor (AR) sensitive and AR resistant prostate cancer cell lines. These data support advancing AUTX-703 into clinical development for multiple sub-types of prostate cancer. 'These preclinical data show that AUTX-703 can effectively inhibit growth in multiple prostate cancer models, offering a novel approach to tackling these challenging cancers by targeting cell-state plasticity through KAT2A/B degradation,' said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron. 'As we advance our first Phase 1 clinical trial in hematologic malignancies, these findings reinforce our confidence in AUTX-703's potential to offer meaningful benefits to patients with multiple tumor types facing limited options.' About Auron Therapeutics Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN™ platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors. For more information, please visit and follow us on LinkedIn. Investor Contact: Renee LeckTHRUST Strategic Communicationsrenee@ Media Contact: Carly ScadutoCarly Scaduto ConsultingCarly@
Associated Press
25-02-2025
- Business
- Associated Press
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AUTX-703 for the treatment of patients with relapsed or refractory (r/r) acute myelogenous leukemia (AML). AUTX-703 is a novel, first-in-class, oral KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company has previously presented preclinical data supporting the ability of AUTX-703 to provide a significant survival advantage in AML. Following the FDA's recent clearance of its Investigational New Drug (IND) application, Auron plans to initiate clinical development of AUTX-703 in hematological malignancies in the first quarter of 2025. 'We are gratified by the FDA's recognition of AUTX-703's potential as an important, novel treatment option for relapsed or refractory AML patients, a community that remains in desperate need of new therapies,' said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron. 'The FDA Fast Track Designation underscores the urgent need for innovative treatments for these patients and this milestone comes at a pivotal moment as we prepare to advance AUTX-703 into the clinic. Our team is energized by the potential to bring a first-in-class therapy to patients who have limited effective options today, while simultaneously exploring the broader applications of KAT2A/B modulation.' The FDA's Fast Track program is designed to facilitate the development and expedite the review of medicines with the potential to treat serious or life-threatening conditions and address unmet medical needs. Specifically, Fast Track designation facilitates more frequent interactions with the FDA over the course of a drug's development and enables Accelerated Approval and Priority Review eligibility, if relevant criteria are met. AML is an aggressive blood cancer characterized by the rapid growth of abnormal cells that build up in the bone marrow and interfere with normal blood cell production. Patients with relapsed or refractory AML face particularly poor outcomes, with five-year survival rates of approximately 10%1, highlighting the critical need for novel therapeutic approaches. About Auron Therapeutics Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN™ platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors. For more information, please visit and follow us on LinkedIn. Investor Contact: Media Contact: Carly Scaduto Carly Scaduto Consulting
Associated Press
05-02-2025
- Business
- Associated Press
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing
Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 Series B Financing Funds AUTX-703 Development through Phase 1 Clinical Proof-of-Concept Expanding KAT2A/B Target Opportunity into Autoimmune Indications NEWTON, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced progress for its lead KAT2A/B program and clinical candidate, AUTX-703, and the completion of a $27 million Series B financing. Auron has received clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) and is initiating clinical development of AUTX-703 in hematological malignancies. AUTX-703 is a novel, first-in-class, oral KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. Last December, at the 2024 American Society of Hematology (ASH) Annual Meeting, the Company presented preclinical data supporting the ability of AUTX-703 to provide a significant survival advantage in acute myelogenous leukemia (AML). In addition, the Company intends to study AUTX-703 in patients with solid tumors such as neuroendocrine prostate and small-cell lung cancer. Proceeds from the raise will be used to advance AUTX-703 through a Phase 1 clinical proof-of-concept trial in AML, which will begin enrolling patients in the first quarter of this year. In addition, funds will be used to evaluate the therapeutic potential of targeting KAT2A/B in autoimmune disease and advance drug discovery efforts of novel EMT tumor targets identified using AURIGIN. 'I'm proud of the work the Auron team has done establishing a strong product profile for AUTX-703, using an innovative approach to cell state biology to tackle some of the deadliest cancers,' said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron. 'With the funding from this raise, we're ready to advance AUTX-703 into clinical trials for hematological malignancies and evaluate the promising potential of KAT2A/B in treating inflammatory conditions, all in pursuit of our mission to deliver transformative medicines to patients.' 'The power of Auron's approach lies in its ability to leverage novel biological insights, enabling the discovery of validated therapeutic targets, optimized model systems for early de-risking, and biomarkers that guide precise patient selection,' said Serge Messerlian, Operating Partner at DCVC Bio and Auron Board Director. 'As the demand for targeted therapies and patient-specific trials continues to grow, Auron is uniquely positioned to address these critical needs. We are very impressed by the progress made across the Company's founding scientific hypothesis, novel platform, and pipeline, led by AUTX-703, and are excited to collaborate with Kate and the Auron team in this next phase of their growth.' The Series B financing was led by DCVC Bio with additional support from Apollo Health Ventures, Arkin Bio Ventures, BrightEdge (the investment arm of the American Cancer Society), Casdin Capital, Franklin Berger, Mubadala Capital, Polaris Partners and Qiming Venture Partners USA. About Auron Therapeutics Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN™ platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors. For more information, please visit and follow us on LinkedIn. THRUST Strategic Communications Media Contact: Carly Scaduto
